STAT

Innovative therapies require innovative thinking on access and cost

Americans should have affordable access to innovative, disease-altering therapies. Achieving that will require innovative approaches.
Source: FRED DUFOUR/AFP/Getty Images

When it comes to improving human health, I believe that Americans agree on three fundamental principles:

  • Vigorous pursuit of innovation and breakthroughs will improve health and benefit patients, the health care system, and our society.
  • New and better medicines can transform the treatment of devastating diseases and increase competition among innovators, ultimately leading to better patient outcomes and lower health care costs.
  • All Americans should have access to affordable and effective treatments.

As a nation, we are making great progress on the first two principles. My company, Celgene, is one of many biopharmaceutical companies that are pushing, up to 70 percent of which could be first-in-class therapies for cancer, cardiovascular diseases, inflammatory conditions, and many other unmet medical needs.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks